Objective To investigate the clinical effect and safety of compound glycyrrhizin combined with bozhi glycopeptide in treatment of erythema nodosum.Methods Sixty-four patients with erythema nodosum were divided into treatment group (36 cases) and control group (28 cases) by random digits table method.The patients in treatment group were given compound glycyrrhizin 120 mg,intravenous drip,once a day;and bozhi glycopeptide 4 ml,intravenous drip,once a day.The patients in control group were given compound glycyrrhizin 120 mg,intravenous drip,once a day.The clinical efficacy and recurrence were compared between 2 groups.Results The total effective rate in treatment group was significantly higher than that in control group [86.1％ (31/36) vs.57.1％ (16/28)],there was statistical difference (P ＜ 0.05).Follow-up for 3 months,the rate of recurrence in treatment group was significantly lower than that in control group [16.1％(5/31) vs.8/16],there was statistical difference (P＜ 0.05).Conclusion Compound glycyrrhizin combined with bozhi glycopeptide can effectively control the erythema nodosum,and has no significant adverse reactions,reduces the rate of recurrence,and it is worthy of promotion and application.

Objective To investigate the inhibition of lymphoid enhancer factor-1 (LEF-1) expression in human malignant melanoma cell line A375 by RNA interference method. Methods Sense and antisense oligonucleotides with hairpin structures, targeted specifically at LEF-1 mRNA, were designed, synthesized, then linked to the expression vector psilencer3.1-H1 neo after annealing. After identification, the re-combinant psilencer3.1-H1/LEF-1 siRNA was used to transfect the cultured A375 cells by a liposome-medi-ated method. The cells expressing the recombinant RNA was detected by G418 screening. The mRNA and protein levels were detected by RT-PCR, Western blotting and immunocytochemistry, respectively. Results The expression vector psilencer3.1-H1/LEF-1 siRNA was successfully constructed, and its stable expression in cell clones was achieved. The mRNA and protein levels of LEF-1 were both down-regulated in the trans-fected cells. Conclusion The recombinant of psilencer3.1-HI/LEF-1 siRNA can inhibit the mRNA and protein expression of LEF-1 in A375 cells.

Objective To investigate ?-catenin and lymphoid enhancing factor 1 (LEF-1) expression in malignant melanoma. Methods ?-catenin and LEF-1 protein expression was examined using the PowerVisionTM immunohistochemical method in 25 cases of intradermal nevus and 45 cases of malignant melanoma. Results Comparing malignant melanoma with intradermal nevi, there was a significant difference in the expression of ?-catenin (33/45= 73% vs. 9/25 = 36%, respectively; P

Objective To study the expression of double-stranded RNA-dependent protein kinase (PKR) in malignant melanoma and ordinary nevi. Methods The expression of PKR and proliferating cell nuclear antigen was examined in 42 cases of malignant melanoma and 25 ordinary nevi by an immunohistochemical method. Results The positive rate of PKR expression was higher in the patients with malignant melanoma than that in the patients with ordinary nevi (P